Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carbapenems in paediatrics

J L Blumer1

  • 1Departments of Pediatrics and Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.

Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose.

Clinical pharmacology and therapeutics·2008
Same author

Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties.

Clinical pharmacology and therapeutics·2007
Same author

Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux.

Alimentary pharmacology & therapeutics·2002
Same author

The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.

Journal of clinical pharmacology·2002
Same author

Nosocomial acquisition and transmission of antibiotic-resistant gram-negative organisms in the pediatric intensive care unit.

The Pediatric infectious disease journal·2001
Same author

The pharmacokinetics of colistin in patients with cystic fibrosis.

Journal of clinical pharmacology·2001
Same journal

Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.

Scandinavian journal of infectious diseases. Supplementum·2009
Same journal

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Scandinavian journal of infectious diseases. Supplementum·2009
Same journal

Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Brief summary of the legal proceeding.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Too early or too late: a never-ending dilemma with new technologies.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Genotypic resistance tests for the management of postexposure prophylaxis.

Scandinavian journal of infectious diseases. Supplementum·2004
See all related articles

Meropenem monotherapy is effective and safe for treating serious infections in children, showing comparable results to cefotaxime-based regimens. This carbapenem offers a good option for empiric therapy in pediatric patients.

Area of Science:

  • Pediatric Infectious Diseases
  • Clinical Pharmacology
  • Antimicrobial Therapy

Background:

  • Serious infections in children present unique challenges due to age-related physiological changes.
  • Current multidrug antibiotic therapy is often empiric, lacking confident monotherapy options.
  • Carbapenems demonstrate ideal pharmacokinetic and pharmacodynamic profiles for pediatric serious infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of meropenem monotherapy versus cefotaxime-based regimens in pediatric patients with serious infections.
  • To assess meropenem as a potential monotherapy for empiric treatment in infants and children.

Main Methods:

  • Two multicenter, randomized evaluations compared meropenem monotherapy with cefotaxime-based regimens.
  • Infections treated included lower respiratory tract, urinary tract, intra-abdominal, skin/skin structure, and sepsis.

Related Experiment Videos

  • Efficacy and safety were assessed for both treatment groups.

    • Main Results:

    • Meropenem achieved an overall clinical efficacy rate of 98%, compared to 95% for cefotaxime-based regimens.
    • Both meropenem monotherapy and cefotaxime-based regimens were well-tolerated.
    • No significant clinical or laboratory adverse events were noted for either treatment.

    Conclusions:

    • Meropenem monotherapy is as effective and well-tolerated as cefotaxime-based regimens in pediatric patients.
    • Meropenem represents a viable and potentially advantageous option for empiric therapy in serious pediatric infections.